CCM
CGTX icon

Coldstream Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Coldstream Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,243
Closed -$524 – 1532
2025
Q1 		$524 Buy
+1,243
New +$731 ﹤0.01% 3343

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Coldstream Capital Management's CGTX Position: Q2 2025 in Review

Coldstream Capital Management sold out of Cognition Therapeutics (CGTX) in Q2 2025, closing a stake of 1,243 shares — an estimated $524 sold.

Coldstream Capital Management first reported a position in CGTX in Q1 2025 and held it in 1 quarter. The position peaked at $524 in Q1 2025. 48 funds tracked by Wall St. Rank hold CGTX as of Q2 2025.

  • Coldstream Capital Management reported no remaining Cognition Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 1,243 Cognition Therapeutics shares in Q2 2025, an estimated $524.
  • Coldstream Capital Management first reported a position in Cognition Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Cognition Therapeutics position peaked at $524 in Q1 2025.
  • 48 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.